• +1(847) 967-6000
Containment Performance Verification of the Potent Compound Suite Using Surrogate MonitoringContainment Performance Verification of the Potent Compound Suite Using Surrogate MonitoringContainment Performance Verification of the Potent Compound Suite Using Surrogate MonitoringContainment Performance Verification of the Potent Compound Suite Using Surrogate Monitoring
  • About Regis Technologies
  • About Us
  • Achiral HPLC & SFC Columns
  • Acylation Reagents
  • Additional IAM Columns
  • Alkylation Reagents
  • Analytical Development
  • AZYP Chiral Phases
  • Blog
  • Careers
  • Cart
  • CELERIS™ Amino
  • CELERIS™ Arginine
  • CELERIS™ Diol
  • CELERIS™ Ethyl Pyridine
  • CELERIS™ PEI
  • CELERIS™ Silica
  • Certificates of Analysis
  • CGMP Scale Up
  • Checkout
  • Chiral Applications Database
  • Chiral Derivatization Reagents/Solvents
  • Chiral HPLC & SFC Columns
  • ChiroSil ME®
  • ChiroSil®
  • ChiroSil® Crown Ether Phases
  • ChiroSil® Crown Ether Phases Version 2
  • Clinical Trial Material
  • COA
  • Coelenterazine
  • Coelenterazine References
  • Commercial API
  • Contact Us
  • Crown Ether Phases
  • Custom CGMP API Manufacturing
  • Customer Support
  • Derivatizing Reagents
  • Distributors
  • Elemental Impurities (USP 232-233)
  • Events
  • EVOKE™ C18 Columns
  • Fate and Purge
  • For Anions
    • Bulk Ion Pair Reagents
  • For Cations
    • Bulk Ion Pair Reagents
  • Free Chiral Screening
  • High Potent API Manufacturing
  • History
  • Home v2 – October 2023
  • IAM Literature References
  • Imaging Reagents
  • Immobilized Artificial Membrane (IAM) Chromatography
  • IND Enabling Supply
  • Ion Pairing Reagents
  • Literature Library
    • Catalog and Brochures
    • Custom Pharma
    • Product Information
    • Technical Resources
  • Luciferin
  • Luciferin References
  • Manufacturing Facility Details
  • Milling
  • News
  • Orphan & Fast Track
  • Other Chiral Phases
  • Our Team
  • Privacy Policy
  • Process Chemistry
  • Products
  • Project Management
  • Q-Series
  • Quality Assurance
  • Quality Control
  • REFLECT™ Coated
  • REFLECT™ Immobilized
  • REFLECT™ Polysaccharide Phases
  • Regis Chromatography
  • Regis Custom API
  • Regis Facility Tour
  • Request Chiral Handbook for HPLC & SFC Separations
  • Request Chiral Method Development Posters
  • Resources
  • Return Policy
  • Reversed-Phase HPLC Columns
  • Safety Data Sheets (SDS)
  • Search
  • Services
  • Services 2 New Custom API landing page
  • Silylation Reagents
  • Site Map
  • Solid State Chemistry
  • Stability Services
  • Structure Elucidation and Impurity Services
  • Synthesis Reactions And Equipment
  • System Suitability And Validation For Chiral Purity Assays Of Drug Substances
  • Terms & Conditions
  • Tools for Drug Discovery
  • Video Library
  • WHELK-O®1
0

Containment Performance Verification of the Potent Compound Suite Using Surrogate Monitoring

May 8, 2015

As part of commissioning of the Regis’ Potent Compound Suite 1 (PCS1), an industrial hygiene monitoring was performed by Safebridge Consultants, Inc., on March 4 and 5 of 2015 with the purpose to evaluate the containment performance of the facility. Based on the occupational exposure limits (OELs) of the future Active Pharmaceutical Ingredients (APIs) to be handled, a containment performance target (CPT) was set to 50 ng/m3. The objective of containment performance verification was to show that the CPT has been achieved.

The surrogate monitoring involved handling of surrogate material (naproxen sodium) in PCS1 by Regis’ employees, while performing the air and surface sampling by certified industrial hygienist in order to find out how much of material is escaping from the containment. The typical operations have been simulated three times, using a different operator for each assessment. The sampling strategy included collection of the following samples: background air, personal (breathing zone), general area, and surface wipe samples. The results of the study offer an estimate how efficiently the equipment will contain the potent APIs under similar circumstances.

The benefits of surrogate monitoring are:

  • Containment evaluation of new equipment without potential for employee exposure to potent API
  • Testing in instances when a validated method has not been developed for the compound of interest, which is typical for the early stages of drug development
  • Using an appropriate surrogate (less potent) material with very low limits of detection, to challenge installations. The limit of quantification (LOQ) for an air sample was 0.0500 ng. The LOQ for a surface sample was 0.500 ng.

The containment performance report was provided by SafeBridge Consultants, Inc. The report describes the testing methodology and provides an objective interpretation of the results indicating that the containment performance of the equipment is in full compliance with the Regis’ containment performance target (CPT) of 50 ng/m3. Personal and area measurements for surrogate powder handling showed that containment isolator system in the PCS1 can be used to handle a wide range of potent APIs. The surface sampling results were found to be well below the performance-based acceptable surface limit (ASL) for SafeBridge Category 3 (Regis HHC 4) compounds. This evaluation gives further confidence that potent APIs are being handled safely at Regis Technologies, protecting employees, products, and environment.

Share

Information

About Us

Contact Us

8210 Austin Ave
Morton Grove, IL 60053

+1(847) 967-6000
sales@registech.com

Find a Distributor

E-Mail Sign Up






     

     

    Website Created by Advanta Advertising, LLC.
    © 2025 Regis Technologies Inc. All Rights Reserved
    Contact Us
      0

      [ Placeholder content for popup link ] WordPress Download Manager - Best Download Management Plugin

      The Regis Technologies Website is set to allow the use of cookies. Cookies help us to give you the best experience on our website. By clicking Accept or continuing to use the site, you agree to use our cookies. If you decline we will not track your information but your browsing experience might be limited. Please visit our Terms & Conditions and our Privacy Policy for more information.AcceptDecline